National Music Publishers' Association

Jon Platt to Receive GRAMMY Salute To Industry Icons® Honor at the 2024 Pre-GRAMMY® Gala

Retrieved on: 
Thursday, December 7, 2023
Music, Professional Services, Philanthropy, Publishing, Arts, Museums, Events, Concerts, Entertainment, Celebrity, Communications, DEI (Diversity, Equity and Inclusion), Fund Raising, EMI Music Publishing, BeatStars, The Recording Academy, Public Enemy, National Music Publishers' Association, DIY, Organization, City, WWE Hall of Fame, Songwriter, Forward, NMPA, IBM, Multimedia, Mastercard, Central Cee, Berklee College of Music, SONA, Hitsville U.S.A., SAT, Nashville Songwriters Association International, Kid, Usher, France 4 Visionary Award, University, Songwriters Hall of Fame, Warner Chappell Music, Arrested Development, Sony Music Publishing, Mental health, SMP, Female, NSAI, Reasonable doubt, Latto

Commended for his indisputable impact on the music business, Sony Music Publishing Chairman and CEO Jon Platt is the 2024 GRAMMY Salute To Industry Icons® honoree.

Key Points: 
  • Commended for his indisputable impact on the music business, Sony Music Publishing Chairman and CEO Jon Platt is the 2024 GRAMMY Salute To Industry Icons® honoree.
  • The Recording Academy® and Clive Davis will celebrate Platt’s achievements at the renowned Pre-GRAMMY® Gala on Sat, Feb. 3, 2024, the evening preceding the 66th Annual GRAMMY Awards®.
  • In 2005, he launched The Big Jon Platt Scholarship Program for college-bound students from his Denver community in Montbello.
  • For the past decade, the invitation-only Pre-GRAMMY Gala has included a presentation to honor industry luminaries through the Recording Academy's GRAMMY Salute To Industry Icons award.

Songclip and Hipgnosis Announce Partnership to Facilitate Licensing and Compliance of Hipgnosis Catalogue Across the Global App Marketplace

Retrieved on: 
Thursday, October 13, 2022
Professional Services, Entertainment, Technology, Music, Audio, Video, Venture Capital, Licensing (Entertainment), Emotion, API, NMPA, UMG, Sanctuary Group, Nile Rodgers, The Advisory Board Company, Hipgnosis Songs Fund, Merck Mercuriadis, Metadata, Catalog, Financial adviser, Song, Multimedia, Music, Partnership, Technology, National Music Publishers' Association, Knowledge, Publishing, WMG, AI, CEO, Warner Chappell Music, UMPG, IP, Social media, BMG, Heart, Compliance, Online shopping, Hipgnosis, Kobalt

Songclip works in partnership with all major music rights holders to provide a streamlined solution for licensing and integrating music within consumer applications.

Key Points: 
  • Songclip works in partnership with all major music rights holders to provide a streamlined solution for licensing and integrating music within consumer applications.
  • Songclips technology suite manages search & discovery, catalogue & compliance, licensing, royalty payments, reporting and end-user analytics ensuring all music is properly accounted for and licensed.
  • Songclip represents the industry-backed solution for making sure apps can easily integrate music, with proper licensing, compliance and payment back to rights holders.
  • Songclips plug-and-play API seamlessly integrates into apps and social platforms to facilitate licensing, search, catalog and compliance, royalty payments, reporting, and end-user analytics.

Songclip Announces Strategic Partnership With the NMPA to Bring Music Licensing and Compliance to the App Marketplace

Retrieved on: 
Thursday, June 16, 2022
Software, Online, Entertainment, Mobile Entertainment, Social Media, Professional Services, Venture Capital, Apps, Applications, Technology, Music, Audio, Video, Communications, Licensing (Entertainment), Music, UMG, Catalog, NMPA, Association, View, Compliance, Metadata, CEO, Entrepreneurship, API, National Music Publishers' Association, Warner Chappell Music, New, Partnership, AI, WMG, Communication, UMPG, BMG, Video game, Kobalt

Songclip, the worlds only patented music clip company, today announced a strategic partnership with The National Music Publishers Association (NMPA), the trade association representing all American music publishers and their songwriting partners.

Key Points: 
  • Songclip, the worlds only patented music clip company, today announced a strategic partnership with The National Music Publishers Association (NMPA), the trade association representing all American music publishers and their songwriting partners.
  • The partnership aims to facilitate music licensing and compliance within the global app marketplace.
  • Israelite also announced that Songclip will be a strategic partner of NMPA to facilitate licensing across the app marketplace.
  • The Songclip API seamlessly integrates into any app, manages and facilitates search, catalog & compliance, licensing, royalty payments and reporting.

ASCAP ELEVATES THREE EXECUTIVES TO SENIOR VICE PRESIDENT

Retrieved on: 
Wednesday, January 26, 2022
Data collection, View, Mark (given name), SVP, International relations, Grout, Internet, ASCAP, Strategic planning, Industry, Planet Records, Columbia University, Restaurant, State University of New York at Oneonta, Luca Filippi, Senior, Member, Composer, Twitter, Multimedia, National Music Publishers' Association, Growth, American Society of Composers, Authors and Publishers, Music, College of William & Mary, Instagram, Radio, Rodda, College, Goal, PRO, Florida International University, Society, Business, Public relations, Management, Publishing, License, Facebook

Elizabeth Roddais based in Miami and reports to Tony Dunaif, ASCAP Executive Vice President of International Affairs.

Key Points: 
  • Elizabeth Roddais based in Miami and reports to Tony Dunaif, ASCAP Executive Vice President of International Affairs.
  • As Senior Vice President, Rodda will work to optimize international revenue for ASCAP's members.
  • Matt DeFilippis, based in New York, reports to ASCAP Executive Vice President of Licensing, Stephanie Ruyle.
  • In his role as Senior Vice President, DeFilippis will be responsible for revenue from some of the industry's largest platforms, including digital audio and audio-visual streaming platforms, and traditional audio-visual and audio.

Certara to Acquire Pinnacle 21, a Leader in Data Standardization Software for Pharmaceutical Clinical Data

Retrieved on: 
Thursday, August 5, 2021
Company, Chief executive officer, Statistics, Efficiency, Pinnacle, Clinical trial, Webcast, Forward-looking statement, Phrase, Earnings before interest, taxes, depreciation and amortization, Community, Organization, Technology, Adoption, Machine learning, Jefferies Group, Software, Clinical Data Interchange Standards Consortium, Growth, Patient, US Foods, Drug discovery, Medicines and Healthcare products Regulatory Agency, Food and Drug Administration, Risk, PMDA, Simpson Thacher & Bartlett, Nasdaq, Drug development, R, Compliance, National Music Publishers' Association, Conference, Doctor of Philosophy, Private Securities Litigation Reform Act, Acquisition, GLOBE, Medical device, Pharmaceutical industry

Pinnacle 21 is a leader in biopharmaceutical data fitness, which streamlines quantitative analyses needed by our clients.

Key Points: 
  • Pinnacle 21 is a leader in biopharmaceutical data fitness, which streamlines quantitative analyses needed by our clients.
  • The acquisition will immediately establish Certara as a central participant in the data standardization process across the entire drug development life cycle.
  • Certara is the ideal partner for Pinnacle 21s exceptional team and customer base, said Max Kanevsky, Founder and CEO of Pinnacle 21.
  • Pinnacle 21 is a global leader in software for preparing clinical trial data for regulatory submission.

Promega and Henlius Developing Microsatellite Instability Companion Diagnostic IVD Kit for Serplulimab in China

Retrieved on: 
Thursday, August 5, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Medical Devices, Genetics, Neutralizing antibody, IVD, Research, Promega, Industry, Oncology, IgG4-related ophthalmic disease, Degenerative disease, Technology, Polymerase chain reaction, Union, MMR, Cell biology, Government, Mab, NDAS, Review, GMP, ICI, National Medical Products Administration, Laboratory, Patient, US Foods, Neoplasm, Cancer, Genome, Mainland China, New Drug Application, DNA replication, Food and Drug Administration, Multiplex polymerase chain reaction, RNA, Immunotherapy, Microsatellite instability, DNA, Renal cell carcinoma, NDA, Drug development, National Music Publishers' Association, United Kingdom, R, Marie Cassidy, MSI, Vaccine, Pharmaceutical industry, Fine chemical, Promega, Henlius, PROMEGA, HENLIUS

Shanghai Promega Biological Products Co., Ltd. and Shanghai Henlius Biotech, Inc. will develop and commercialize a microsatellite instability (MSI) companion diagnostic IVD kit to identify cancer patients likely to benefit from serplulimab, a novel anti-PD-1 monoclonal antibody (mAb) developed by Henlius for the potential treatment of microsatellite instability-high (MSI-H) solid tumors.

Key Points: 
  • Shanghai Promega Biological Products Co., Ltd. and Shanghai Henlius Biotech, Inc. will develop and commercialize a microsatellite instability (MSI) companion diagnostic IVD kit to identify cancer patients likely to benefit from serplulimab, a novel anti-PD-1 monoclonal antibody (mAb) developed by Henlius for the potential treatment of microsatellite instability-high (MSI-H) solid tumors.
  • The kit will be available to doctors in the Chinese Mainland to screen for MSI and inform immunotherapy options.
  • The New Drug Application (NDA) of serplulimab was recently granted priority review by the National Medical Products Administration (NMPA) in China.
  • Promega has received innovation status and priority review by the NMPA in China and also intends to seek regulatory clearance for a Promega MSI IVD in China.

BeyondSpring Announces Positive Topline Results from its DUBLIN-3 Registrational Trial of Plinabulin in Combination with Docetaxel for the Treatment of 2nd/3rd Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Wild Type

Retrieved on: 
Wednesday, August 4, 2021
Organic chemistry, Chemistry, Carbonyl compounds, Carbamates, Taxanes, Diketopiperazines, Imidazoles, Plinabulin, Docetaxel

Plinabulin is a first-in-class, selective immunomodulating microtubule-binding agent (SIMBA), which is a potent antigen presenting cell (APC) inducer.

Key Points: 
  • Plinabulin is a first-in-class, selective immunomodulating microtubule-binding agent (SIMBA), which is a potent antigen presenting cell (APC) inducer.
  • The DUBLIN-3 Phase 3 trial is a randomized, single blind to patients, active controlled, global trial that enrolled 559 patients in 2nd and 3rd line NSCLC, EGFR wild type, with measurable lung lesion.
  • Plinabulin in combination with docetaxel (DP) showed statistically significant improvements compared to docetaxel alone (D) with topline data summarized below for ITT population (DP: n=278; D: n=281).
  • Now that checkpoint inhibitor immunotherapy has moved into first line, there is a vacuum in this indication, where treatment is heavily centered around docetaxel.

NMPA’s Center for Drug Evaluation Adds Licenses of GastroPlus®

Retrieved on: 
Wednesday, August 4, 2021
Biotechnology, Health, Pharmaceutical, Technology, Software, Simulation software, Simulations Plus, Health sciences, Pharmacokinetics, NMPA, National Medical Products Administration, Simulation, Bioequivalence, Life sciences, Health

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that it has received an order from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China to add licenses to GastroPlus.

Key Points: 
  • Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that it has received an order from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China to add licenses to GastroPlus.
  • We have cultivated relationships with different affiliated institutions of NMPA to apply our technology to support the evaluation of drug product specifications and bioequivalence.
  • Now, researchers at the CDE will add GastroPlus to serve as a key platform for model-informed drug development (MIDD) to aid regulatory reviews.
  • Serving clients worldwide for 25 years, Simulations Plus, Inc., is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions.

111, Inc. Enters into Strategic Cooperation Agreement with Zelgen to Develop a New Management Platform for Liver Cancer Patients in China

Retrieved on: 
Tuesday, August 3, 2021
Cancer, Clinical medicine, Medical specialties, Health, Liver cancer, Oncology

The agreement will allow 111 and Zelgen to build an innovative out-of-hospital, virtual management platform for liver cancer patients that integrates doctor resources, doctor-patient interaction, convenient access to medicines, and education resources.

Key Points: 
  • The agreement will allow 111 and Zelgen to build an innovative out-of-hospital, virtual management platform for liver cancer patients that integrates doctor resources, doctor-patient interaction, convenient access to medicines, and education resources.
  • Liver cancer has become the second most fatal cancer in China.
  • Out of 3 million cancer deaths in 2020, about 390,000 were from liver cancer, second only to lung cancer.
  • Dr. SHENG Zelin, Chairman and General Manager of Zelgen, commented, "Zelgen is an innovative pharmaceutical company focused on research and development of new drugs.

WuXi Biologics Biosafety Testing Facility Received Second EMA GMP Certificate

Retrieved on: 
Monday, August 2, 2021
Life sciences, Biotechnology, WuXi Biologics, Jiangnan, Yangtze River Delta, Articles, Pharmaceutical industry, Biopharmaceutical, Wuxi, Suzhou, European Medicines Agency, WuXi AppTec

SUZHOU, China, Aug. 2, 2021 /PRNewswire/ --WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that only 13 months after receiving its first GMP certificate, it has once again received a European Medicines Agency (EMA) GMP certificate for the Biosafety Testing facility in Suzhou.

Key Points: 
  • SUZHOU, China, Aug. 2, 2021 /PRNewswire/ --WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that only 13 months after receiving its first GMP certificate, it has once again received a European Medicines Agency (EMA) GMP certificate for the Biosafety Testing facility in Suzhou.
  • This certificate demonstrates WuXi Biologics' compliance to global cGMP biosafety testing standards and regulatory guidelines.
  • Dr. Chris Chen, CEO of WuXi Biologics, commented, "The second EMA certificate is the solid proof of our world-class quality system as well as the technology platforms utilized at our Suzhou facility.
  • WuXi Biologics Biosafety Testing team offers cell line characterization and adventitious agent testing for the QC release of cell banks, unprocessed bulk (UPB) lots and raw materials.